WHO ICTRP trial
Oleoylethanolamide supplementation in women with the poly cystic ovarian…
IRCT20141025019669N20 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT20141025019669N20 |
|---|---|
| Public title | Oleoylethanolamide supplementation in women with the poly cystic ovarian syndrome |
| Scientific title | Survey the effect of oleoylethanolamide on fasting blood sugar level, insulin resistance, lipid profile, oxidative stress status, inflammatory factors, sex hormones levels and anti-Mullerian hormone in women with poly cystic ovarian syndrome |
| Primary sponsor | Qazvin University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | 2-3 |
| Countries | Iran (Islamic Republic of) |
| Conditions | Poly cystic ovarian syndrome. Polycystic ovarian syndrome;E28.2 |
| Interventions | Intervention 1: Intervention group: Oleoylethanolamide, a capsule 200 mg per daily for two months, Manufacturer: Supplement Spot. Intervention 2: Control group: A daily placebo capsule containing wheat flour for two months. |
| Registration date | Jan 9, 2022 |
| Target size | 80 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: